294 related articles for article (PubMed ID: 9351353)
21. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men.
Millar JS; Lichtenstein AH; Cuchel M; Dolnikowski GG; Hachey DL; Cohn JS; Schaefer EJ
J Lipid Res; 1995 Jun; 36(6):1155-67. PubMed ID: 7665994
[TBL] [Abstract][Full Text] [Related]
22. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
Ruel IL; Lamarche B; Mauger JF; Badellino KO; Cohn JS; Marcil M; Couture P
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2600-7. PubMed ID: 16224048
[TBL] [Abstract][Full Text] [Related]
23. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins.
Vega GL; Krauss RM; Grundy SM
J Intern Med; 1990 Feb; 227(2):81-94. PubMed ID: 2105373
[TBL] [Abstract][Full Text] [Related]
24. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects.
Watts GF; Naoumova RP; Kelly JM; Riches FM; Croft KD; Thompson GR
Am J Physiol; 1997 Sep; 273(3 Pt 1):E462-70. PubMed ID: 9316434
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
[TBL] [Abstract][Full Text] [Related]
27. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
[TBL] [Abstract][Full Text] [Related]
28. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis.
Ginsberg HN; Le NA; Short MP; Ramakrishnan R; Desnick RJ
J Clin Invest; 1987 Dec; 80(6):1692-7. PubMed ID: 3680522
[TBL] [Abstract][Full Text] [Related]
29. Mevinolin and cholestyramine inhibit the direct synthesis of low density lipoprotein apolipoprotein B in miniature pigs.
Huff MW; Telford DE; Woodcroft K; Strong WL
J Lipid Res; 1985 Oct; 26(10):1175-86. PubMed ID: 3906004
[TBL] [Abstract][Full Text] [Related]
30. Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects.
Ooi EM; Janus ED; Grant SJ; Sinclair LM; R Barrett PH
J Lipid Res; 2010 Aug; 51(8):2413-21. PubMed ID: 20413671
[TBL] [Abstract][Full Text] [Related]
31. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
[TBL] [Abstract][Full Text] [Related]
32. Lipoprotein metabolism in subjects with hepatic lipase deficiency.
Tilly-Kiesi M; Schaefer EJ; Knudsen P; Welty FK; Dolnikowski GG; Taskinen MR; Lichtenstein AH
Metabolism; 2004 Apr; 53(4):520-5. PubMed ID: 15045702
[TBL] [Abstract][Full Text] [Related]
33. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss.
Ginsberg HN; Le NA; Gibson JC
J Clin Invest; 1985 Feb; 75(2):614-23. PubMed ID: 3973021
[TBL] [Abstract][Full Text] [Related]
34. Dietary fish oil plus lovastatin decreases both VLDL and LDL apo B production in miniature pigs.
Huff MW; Telford DE; Barrett PH
Arterioscler Thromb; 1992 Aug; 12(8):902-10. PubMed ID: 1637788
[TBL] [Abstract][Full Text] [Related]
35. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome.
Toto RD; Grundy SM; Vega GL
Am J Nephrol; 2000; 20(1):12-7. PubMed ID: 10644862
[TBL] [Abstract][Full Text] [Related]
36. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
[TBL] [Abstract][Full Text] [Related]
37. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis.
de Sain-van der Velden MG; Kaysen GA; Barrett HA; Stellaard F; Gadellaa MM; Voorbij HA; Reijngoud DJ; Rabelink TJ
Kidney Int; 1998 Apr; 53(4):994-1001. PubMed ID: 9551409
[TBL] [Abstract][Full Text] [Related]
38. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Bell DS
Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642
[TBL] [Abstract][Full Text] [Related]
39. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications.
Watts GF; Cummings MH; Umpleby M; Quiney JR; Naoumova R; Thompson GR; Sönksen PH
Eur J Clin Invest; 1995 Aug; 25(8):559-67. PubMed ID: 7589011
[TBL] [Abstract][Full Text] [Related]
40. Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia.
Elias N; Patterson BW; Schonfeld G
Arterioscler Thromb Vasc Biol; 1999 Nov; 19(11):2714-21. PubMed ID: 10559016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
